卖什么
Cancer Diagnosis 10X faster, 10X cheaper
商业模式拆解
买家：谁掌握预算？
未核实Lab directors/pathologists buying an on-site DNA+RNA NGS workflow; biopharma clinical teams for trial profiling.
触发点：什么让他们现在购买？
Shipping samples to reference labs delays results; labs want in-house NGS validated in under two months with MolDX submission support.
工作流：什么输入变成什么输出？
One prep for DNA and RNA, overnight sequencing on-site, report next day in Duoseq Suite with EPIC/EHR integration; under 10 minutes of technician time on lab robotics.
经济账：省了什么，怎么收费？
Claims 10x cheaper and 10x faster cancer genomics (sample to report in 2 days); likely sells assay/kit plus software and services to labs and biopharma.
渠道：怎么接触到客户？
Contact-us led direct sales to labs, plus biopharma partnerships with custom trial portals and regulatory/biomarker support.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2018 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.